Category: Media

Dr. Angie Beltsos Named Top Doctor in Chicago

We are excited to announce Dr. Angie Beltsos has been recognized in Chicago Magazine as one of the Top Doctors in the Chicago area.

Dr. Beltsos is the CEO and Chief Medical Officer of Vios Fertility Institute. She is double board certified in Obstetrics and Gynecology and in Reproductive Endocrinology and Infertility (REI).

To learn more about Dr. Beltsos, click here or schedule an appointment with her now.

Dr. Beltsos was chosen by Castle Connolly Medical Ltd., a leading research and information resource for patients looking to find the best medical care. Doctors do not pay to appear on Castle Connolly lists. Castle Connolly selects the list of Top Doctors based on peer nomination, research, review, and screening.

Congratulations Dr. Beltsos on your selection!

Dr. Ellen Hayes Named Top Doctor in Milwaukee

We are excited to announce Dr. Ellen Hayes has been recognized in Milwaukee Lifestyle Magazine as one of the Top Doctors in the Milwaukee area.

Dr. Hayes received her medical degree from Loyola University Chicago Stritch School of Medicine and completed her residency in Obstetrics and Gynecology at Medical College of Wisconsin. She completed her fellowship in Reproductive Endocrinology and Infertility at Emory University Medical Center.

To learn more about Dr. Hayes, click here or schedule an appointment with her now.

Dr. Hayes was chosen by Castle Connolly Medical Ltd., a leading research and information resource for patients looking to find the best medical care. Doctors do not pay to appear on Castle Connolly lists. Castle Connolly selects the list of Top Doctors based on peer nomination, research, review, and screening.

Congratulations Dr. Hayes on your selection!

Kindbody and Vios Fertility Institute Create Largest Women-led Fertility Care Company Serving Employers and Consumers

Kindbody Expands National Footprint with $1.15 Billion Valuation

NEW YORK, February 1, 2022 — Kindbody, a leading fertility and family-building care company, today announced that it has signed a merger agreement to acquire Vios Fertility Institute, a high-growth, innovative network of fertility clinics, to increase access to patient-centric, technology-driven care across the country. The transaction doubles Kindbody’s national footprint to 26 clinics with plans to expand to 40 retail locations by year’s end. Together, the companies performed nearly 10,000 fertility treatments in 2021 and served thousands of patients via their virtual and in-person services and is projected to double that in 2022.

Kindbody and Vios are both women-led companies driven by a mission and vision to revolutionize fertility care. Kindbody has transformed the fertility landscape through its design-forward clinics, state-of-the-art technology, and comprehensive virtual, at-home, and in-person care. Under the leadership of global fertility leader, Dr. Angeline Beltsos, Vios has developed deep experience and proven success in clinical operations, innovation, and scale. Vios clinics, located in Illinois, Michigan, Missouri, Oregon, Washington, and Wisconsin, will rebrand to Kindbody and integrate Kindbody’s proprietary patient portal, EMR (electronic medical record), and telehealth platform into the expanded operations to ensure a seamless continuum of care. 

As part of the transaction, Dr. Beltsos will become Chief Executive Officer, Clinical, designing and leading Kindbody’s medical team. Annbeth Eschbach has been promoted from President to Chief Executive Officer, Corporate, and will ensure operational excellence and consistent growth across the country; and, Vios President Gregory Poulos will assume the role of President of the combined company. Gina Bartasi, Kindbody’s Founder and CEO, will oversee a newly formed holding company leading expansion and vision for the combined entity.

“We founded Vios with a mission of an unparalleled patient experience and a vision of building families dreamed of by our patients,” said Dr. Angeline Beltsos, Founder and CEO of Vios. “Now, more people will have access to the personalized, high-touch experience they have come to expect from both Kindbody and Vios. Together, we have the opportunity to revolutionize fertility and family-building care and make it more accessible for all. I’m excited for what the future holds.“ 

Incoming Chief Executive Officer, Corporate, Annbeth Eschbach said, “We welcome Dr. Beltsos and the entire innovative Vios team to Kindbody. This union brings together two organizations with shared values and alignment around unwavering empathy for patient experience and outcomes. Together, we double our size, reach, and strengths in fertility care to serve our large enterprise clients and more patients everywhere.”

In addition to its proprietary technology, Kindbody has 78 employer clients serving more than 350,000 covered lives. “Large employers have been asking for more Kindbody locations to serve their employees and now, together with Vios, we’re better able to meet this demand. Angie is one of a kind and we couldn’t be more aligned philosophically around patient-centered care. After more than a decade of friendship and respect for her work, I’m thrilled to bring together our combined strengths to further accelerate our mission to make fertility care more affordable and accessible for all,” added Gina Bartasi.

Last year was a record year for consolidation in the digital healthcare sector with M&A activity up 44% from 2020, according to CB Insights State of Digital Health 2021 report. Investments in the US digital health market also skyrocketed in 2021 reaching a record $37.9B. The number of global digital health “unicorns,” or startups that reach a valuation of $1B, reached a record of 85, up 49% over the previous year, according to the report. Kindbody is uniquely positioned for success in the digital healthcare sector because it provides both care navigation and care delivery with more than 64 providers across the country. The announcement follows Kindbody’s expansion into at-home testing earlier this month, beginning with fertility hormone test kits for women and men. 

Kindbody was founded in 2018 and is led by a best in class leadership team including Founder and Chair, Gina Bartasi; CEO, Corporate, Annbeth Eschbach; CEO, Clinical, Dr. Angeline Beltsos; President, Gregory Poulos; Chief Medical Officer, Dr. Lynn Westphal; Chief Innovation Officer, Dr. Fahimeh Sasan, Chief Business and Legal Officer, Shilpa Patel; Chief Scientific Officer, Dr. Dean Morbeck; Chief Revenue Officer, Taryn Branca; Chief Marketing Officer, Anna Levikova; Chief Technology Officer, Richard Forsythe; Chief Accounting Officer, Brian Goldfarb; Chief Strategy Officer, Hannah Johnson; Chief Genomics Officer, Dr. Amber Cooper; Chief Clinical Research Officer, Dr. Roohi Jeelani; and Chief Financial Officer, Meredith Whitney. Kindbody’s Advisory Board includes Dr. Jacques Cohen, Larry Leisure, Cindy Gentry, Kerry Van Voris, Kimber Lockhart and Andy Grover. 

About Vios Fertility Institute

Established in 2015, Vios Fertility Institute is one of the fastest growing fertility clinics in the U.S. with 13 locations in the Chicago, Detroit, Milwaukee, Portland, and St. Louis regions. Woman owned, the Vios mission is to help patients find their way to fertility health with the highest chances of success. Vios offers innovative, scientific, and cutting-edge treatment options along with an unparalleled patient experience. Visit www.ViosFertility.com to learn more.

About Kindbody

Kindbody is a leading fertility and family-building care company offering state-of-the-art technology, comprehensive virtual and in-person care, and an employer benefits solution. Kindbody’s clinically managed program includes fertility assessments and education, fertility preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption, as well as physical, mental, and emotional support from preconception through postpartum. Kindbody is the trusted fertility benefits solution for more than 78 employers, covering more than 350,000 lives. Many thousands more receive their fertility care directly from Kindbody throughout the country at signature clinics, mobile clinics, and partner clinics. As the fertility benefits solution, the technology platform, and direct provider of high-quality care, Kindbody delivers a seamless, integrated experience with superior health outcomes at lower cost, making fertility care more affordable and accessible for all. Kindbody has raised $122 million in funding from leading investors including Perceptive Advisors, GV (formerly Google Ventures), RRE Capital, Claritas Health Ventures, Rock Springs Capital, NFP Ventures, and TQ Ventures. Visit www.kindbody.com and follow us on Instagram, Twitter, and Facebook.

Contact: Margaret Ryan, Head of Communications, Kindbody, [email protected]

Vios Fertility- St. Louis Welcomes CryoRobot

Vios Fertility Institute is proud to partner with TMRW to bring their CryoRobot to our St. Louis IVF lab, continuing to provide the best care for patients.

TMRW’s technology provides the world’s first fully automated specimen management platform (CryoRobot) that identifies, tracks, and manages frozen eggs and embryos – central to almost every IVF journey.  Our Chicago lab was the first in the world to adopt this revolutionary technology in early 2021.

“At Vios, we are committed to being an innovative fertility clinic and ensuring patients benefit from the technologies that protect the embryos and eggs they worked so hard to preserve to build their families,” explains Dr. Amber Cooper, Medical and IVF Practice Director of Vios Fertility Institute –St. Louis.  “Our company was the first in the world to embrace this technology because we know how important peace of mind and this protection is for patients.  While human error with manual tanks is rare, even one instance can be catastrophic which is why this new technology-driven platform that delivers digital tracking and thousands of daily safety checks is game-changing for our field.”

Read our full press release here.

Family Building for LGBTQIA+

June marks the beginning of Pride Month, commemorating the Stonewall Riots and celebrating the LGBTQIA+ community. June 1 also is #LGBTQFamiliesDay, created for individuals, families, and allies to celebrate and support LGBTQIA+ families. Family comes in many forms and everyone’s path to their family is unique to their journey. No matter what your journey is, anyone who struggles to build a family should have the opportunity including the LGTBQIA+ community. According to Resolve, between 2 million and 3.7 million children under the age of 18 have a LGTBQIA+ parent.

For most LGTBQIA+ single people and couples, the journey to building your dream family can have a different path than what may be considered “traditional”. At Vios, we are far from “traditional” ourselves and are an ally for the LGTBQIA+ community, here to help those wishing to become parents.

Recently, in the state of Illinois a bill was passed changing the definition of infertility providing insurance coverage to the LGBTQIA+ community. HB3709 amends the IL Insurance Code to provide coverage for the diagnosis and treatment of infertility shall be provided without discrimination on the basis of age, ancestry, color, disability, domestic partner status, gender, gender expression, gender identity, genetic information, marital status, national origin, race, religion, Sex, or sexual orientation. It removes provisions stating that “infertility” means the inability to conceive after one year of unprotected sexual intercourse or the inability to sustain a successful pregnancy. You can read more about this bill here.

There are three necessary components to make a baby: eggs, sperm, and a uterus. Thanks to improved medicine and technology, as well as generosity from third-party donors, same sex couples and single individuals have more options than ever to build the family of their dreams. From sperm donation and IUI, InVoCell for reciprocal IVF, egg donation, and gestational carrier Vios Fertility Institute can help bring the pieces together for all our patients. LGBTQ+ individuals and couples do not necessarily have a diagnosis of infertility so pregnancy rates per cycle are generally high in these cases.

If you need help financing your treatments learn more about our financing partners here!

We Welcome Center for Reproductive Health and Dr. Scott Springer to Our Team

Vios Fertility Institute Physicians, Dr. Springer, Dr. Jeelani, Dr. Beltsos, and Dr. Louden.

We are proud to officially announce the acquisition of Center for Reproductive Health, a widely-respected fertility practice founded by Dr. Scott Springer with locations in Crest Hill, IL and Geneva, IL. Read our full press release here.

A board-certified physician who specializes in Reproductive Endocrinology and Infertility, Springer became disenchanted early in his career with the standard practice business model that had nurses and technicians doing most of the work.  While still early in his career, Springer desired a better way to serve and care for his patients, so in 2001 he introduced the Center for Reproductive Health with a commitment to providing fertility treatments in a one on one personalized patient setting.

Vios is led by CEO and Chief Medical Officer Dr. Angeline Beltsos, who is board certified in Obstetrics and Gynecology and in Reproductive Endocrinology and Infertility (REI), practicing medicine since 1991.  Dr. Beltsos, along with Vios physicians including Dr. Roohi Jeelani and Dr. Erica Louden, will join Dr. Springer in serving patients at the Crest Hill and Geneva locations.

“We are honored to have Dr. Springer join the team and bring his incredible reputation, passion and expertise for building families to Vios,” explains Dr. Beltsos.  “We are excited to partner with him to increase our services and access to fertility care to the Western and Southwest suburbs of Chicago.”

Vios Fertility Institute now has 11 locations in the Chicagoland, Milwaukee, and St. Louis regions and accepts a wide range of insurance options. To schedule an appointment, click here.

Environment, Nutrients and Affects on Fertility: Dr. Amber Cooper Discusses

Age is an important factor in a woman’s ability to get pregnant, but lifestyle may also play a vital role.

Currently, research shows that certain chemicals in our environment could have negative effects on fertility but questions still remain on exactly what harms fertility, how much exposure is dangerous, or when the exposure is dangerous.

Types of chemicals in the environment which have the ability to affect fertility are called Endocrine Disrupting Chemicals (EDCs). These chemicals can be found in food, water, plastics, detergents and more. Once ingested, some of these chemicals may disrupt egg quality or quantity, decrease sperm count, or cause early menopause.

Dr. Amber Cooper, a Vios physician in our St. Louis region, spoke with FOX2 in St. Louis about how environment and nutrition affect fertility. Watch for more information about which chemicals to avoid and lifestyle changes that can help.

After the interview, Dr. Cooper answered patient questions on the topic during a Facebook Live.

Patient FAQs: Egg and embryo storage in the TMRW platform

Vios Fertility Institute is proud to be the first fertility clinic in the world to offer the TMRW Platform to patients. The TMRW platform is the first and only automated technology platform that safely stores, manages, and identifies frozen eggs and embryos. (Read the official press release here.)

What does this mean for Vios patients? See some Frequently Asked Questions and their answers below:

What is the TMRW Platform?

Essentially, it is a high-tech embryo or egg storage tank. Typically, embryos and eggs are frozen and then stored in protective, highly sophisticated, tanks. The TMRW platform is all of this PLUS cutting-edge software – a platform – that continuously monitors and provides 1000s of data points every day to provide real time information about the precious cells stored within. This is the first and only automated platform for the management, identification, and storage of the frozen eggs and embryos used in IVF.

When will eggs or embryos first be stored in the TMRW platform?

The first embryos were moved into the TMRW platform in January, 2021. Patients who have embryos or eggs stored at Vios Fertility Institute through our Chicago IVF Lab will have their tissue placed in the TMRW platform from that point forward and we are transferring our existing inventory of eggs & embryos into the TMRW platform. We expect the TMRW platform to be available in our St. Louis region sometime in 2021.

If I want to move my existing stored embryos or eggs to the TMRW platform, how do I do this?

We are in the process of transferring ALL currently stored eggs & embryos at Vios Fertility Institute Chicago IVF Lab into the TMRW platform. There is no action needed from you, as a patient, to make this happen. We are as excited as you are! If you’d like to talk with your doctor about this, please call and make an appointment.

Does this mean my embryos or eggs aren’t safe where they are currently?

Your embryos and eggs have always been safe. Now, they will be even safer.

Vios has also always upheld the highest levels of safety and security for eggs and embryos stored with us. With the TMRW platform, we have an opportunity to utilize cutting-edge technology to continue to deliver on this promise and provide enhanced monitoring. We are proud to offer it to our patients.

TMRW has created the first and only automated platform for the management, identification, and storage of the frozen eggs and embryos used in IVF.

This does not mean, however, that the current storage system is subpar or ineffective. The standard storage system has been in place – safely – at clinics around the world, including Vios, for many years now. Any tissue stored in these tanks can be assumed to be safe.

The current practices used, however, are manual and labor intensive.

TMRW’s technology automates and digitizes the entire process, which helps reduce the risk for human error and more importantly, allows the clinic to individually track eggs and embryos 24/7 through remote monitoring, sensors and state of the art software.

This technology essentially digitizes an existing system and brings clinics up to speed with the rest of the medical field.

Will use of the TMRW platform increase my frozen egg or embryo storage cost?

The installation of the TMRW platform will not be the cause of a storage price increase.

Over time, storage costs may increase as standard operating costs increase. Information about storage cost is available and you always can discuss this with your healthcare team.

Vios Fertility Institute Patients Are First to Have Embryos Transferred to TMRW

As Egg Freezing and IVF Rates Hit New Highs, Vios Fertility Institute Goes LIVE with TMRW, the World’s First Technology Platform that Stores, Manages, and Identifies Frozen Eggs and Embryos

Chicago Couple is First to Have Embryos Transferred

 

CHICAGO, IL (February 3, 2021) – By the year 2100, approximately 300 million people will be born from in vitro fertilization (IVF), something that seemed impossible until the birth of Louise Brown in 1978. TMRW Life Sciences (“TMRW”) is determined to assist in those future births by effectively managing all frozen fertility specimens with the first and only automated technology platform that safely stores, manages and identifies frozen eggs and embryos. Today, Vios Fertility Institute – Chicago announces it is the first clinic to go live and begin storing patient specimens.

TMRW technology platform at Vios“No one undertaking IVF should ever have to worry about the safety of their embryos and eggs,” said Joshua Abram, Founder and Co-CEO of TMRW. “Three hundred million babies are expected to be born via IVF globally by 2100. With TMRW we have brought the safe storage and management of life’s most precious cells into the 21st Century.”

TMRW is the solution to a wide range of issues that have plagued fertility clinics through the years such as embryo mix-ups, incorrect transfers of embryos and catastrophic failures that resulted in the loss of thousands of irreplaceable eggs and embryos. While current methods are manual and labor intensive, they have remained unchanged since the advent of IVF. TMRW’s technology automates and digitizes the entire process, which helps reduce the risk for human error and more importantly, allows the clinic to individually track eggs and embryos 24/7 through remote monitoring, sensors and state of the art software.

Additionally, TMRW’s automated solution improves IVF by replacing the current archaic system of storage — which is not equipped to handle the soon to be hundreds of millions of fertility specimens — with a cryo-robot featuring secure, reliable technology that dramatically reduces risk and provides peace of mind.

“As we see a substantial increase in patients seeking IVF and in egg freezing – up 41% percent and 31.5% over the previous year – I am thrilled that Vios is the first fertility clinic in the world that offers TMRW to its patients,” explains Dr. Angie Beltsos, CEO & Chief Medical Officer of Vios Fertility Clinic. “IVF patients and those wanting to preserve their fertility deserve the most sophisticated care available, and there is nothing more powerful than combining our top-notch embryology services with TMRW’s game-changing technology. The peace of mind the TMRW platform offers extends to doctors, embryologists and patients alike.”

Chicago couple, Mayrav Dolgin and Renee Genova, have received fertility treatments at Vios Fertility Clinic resulting in two beautiful sons -Jonah age 2 and Elan 6 mos. They are the first patients of Vios to have their remaining embryos stored using TMRW’s new platform.

“The fertility journey can be difficult enough without having to worry about the safety of your embryos,” explains Dolgin. “Mayrav and I were ecstatic to learn that our precious embryos would be the first to be stored in the TMRW cryo-robot,” adds Genova. “Knowing that our remaining embryos will be cared for and looked after with the most advanced technology available gives us tremendous reassurance that our ability to continue building our family in the future is protected.”

The TMRW platform’s key proprietary features include:

  • A 24/7 state-of-the-art, cloud-based monitoring system that makes thousands of wellness checks on stored samples every day. TMRW’s onsite and remote communication system uses predictive analytics to proactively identify and address any safety or storage trends before they become issues.
  • Each patient is assigned an RFID tag with a unique identifier, enabling clinics to identify and track every fertility cell, dramatically reducing the possibility of mislabeled or missing samples.
  • An encrypted, HIPAA-compliant software system, providing the highest level of data privacy and security available.
  • Proprietary labware with thermal properties and proven storage freezer provides the ability to maintain safe cryogenic temperatures to safeguard eggs and embryos even without electrical power or human intervention for more than two weeks, in case of severe emergencies such as natural disasters.

Towards the end of the year, TMRW plans to launch an app that will allow patients to track their frozen specimens using a smartphone. By the end of 2021, TMRW’s platform will be used in leading fertility clinics comprising more than 30% of all IVF cycles in the U.S. The company hopes to expand into UK-based fertility clinics in summer of 2021.

About Vios Fertility:
Established in 2015, Vios Fertility Institute is one of the fastest growing fertility clinics in the U.S. with 11 locations in the Chicago, Milwaukee and St. Louis regions. Woman owned, the Vios mission is to help patients find their way to fertility health with the highest chances of success. Vios offers innovative, scientific, and cutting-edge treatment options along with an unparalleled patient experience. www.ViosFertility.com

About TMRW Life Sciences:
TMRW has created the world’s first automated platform designed specifically for cryo-management of eggs and embryos used in IVF. TMRW’s RFID-enabled, complete digital chain of custody SaaS technology radically improves on the error-prone manual and analog methods that have gone unchanged throughout the history of IVF, significantly reducing the chances of implantation mix-ups or loss of eggs and embryos. The TMRW team includes many of the world’s most celebrated innovators in fertility, embryology, cryo-management, automation, software development and robotics to name a few of the disciplines involved. TMRW’s co-founders, Joshua Abram, Alan Murray, and Dr. Jeffrey Port, are serial tech and life sciences entrepreneurs. Their immediate prior ventures sold for a combined sum of more than $1 billion. To date, TMRW has raised $50 million. For more information, please visit TMRW.org.

 

Miscarriage Treatment Options: Dr. MacKenzie Purdy Answers Your Questions

Miscarriage is a heartbreaking reality for many as they try to conceive and, sometimes, a woman can experience multiple miscarriages in a row.

Recurrent Pregnancy Loss (RPL) is defined by the American Society for Reproductive Medicine (ASRM) as two or more consecutive pregnancy losses. We know this is a heartbreaking loss and we are committed to helping our patients find answers and treatment options to help.

The first step is a series of diagnostic tests to understand what may be causing the miscarriages. There are some common causes of RPL including genetic, hormone imbalance, uterine abnormality, and undiagnosed medical conditions. Some reasons remain unknown despite the myriad of available testing options.

Dr. MacKenzie Purdy, a Vios physician in our St. Louis region, spoke with FOX2 in St. Louis about miscarriage and recurrent pregnancy loss. Watch for more information about diagnosis and testing as well as various treatment options for RPL.

After the interview, Dr. Purdy answered patient questions on the topic during a Facebook Live.